Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) announced inducement awards on May 1, 2026: 53,400 stock options and 11,350 RSUs granted to six newly hired employees under the Vor Biopharma 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Options have a 10-year term and an exercise price of $13.85 (closing price on grant date). Options vest 25% after 12 months, then monthly over 36 months; RSUs vest 25% after 12 months, then quarterly over 36 months, subject to continued employment.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
VOR was down 3.35% while several biotech peers in sector data showed gains: CADL up 14.61%, PRQR up 7.89%, TLSA up 5.30%, ALLO up 5.61%, and SLN up 2.82%. Momentum scanner peers were mixed, with HUMA down and PRQR up, supporting a stock-specific move around VOR rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Inducement grants | Neutral | +3.8% | Announced inducement stock options and RSUs for nine new hires under 2023 plan. |
| Mar 30 | Earnings & update | Positive | +1.5% | Reported Q4/2025 results, strong cash position, and Phase 3 gMG timeline. |
| Mar 30 | Phase 3 trial start | Positive | +1.5% | Dosed first patient in global Phase 3 UPSTREAM SjD trial of telitacicept. |
| Mar 27 | Private placement | Positive | +1.9% | Announced $75M private placement to fund Phase 3 programs and corporate needs. |
| Mar 23 | Inducement grants | Neutral | -4.3% | Disclosed prior inducement stock options and RSUs for new employees. |
Recent news, including prior inducement grants, earnings, a private placement, and Phase 3 trial progress, has generally seen modestly positive or mixed price reactions, with one earlier inducement grant drawing a negative move.
Over the past several weeks, Vor Bio has combined routine equity-related updates with major strategic steps. A $75 million private placement on March 27, 2026 and dosing of the first patient in the global Phase 3 UPSTREAM SjD trial on March 30, 2026 both coincided with modest share gains. Financial results and a corporate update on the same day also saw a positive reaction. By contrast, a March 23, 2026 inducement grant press release was followed by a negative move, while an April 1, 2026 inducement grant drew a small gain, underscoring varied market responses to similar grant announcements.
Regulatory & Risk Context
An effective shelf process was initiated on April 27, 2026 via an S-3 registering up to 5,338,078 shares for resale from the March 30, 2026 private placement. The filing specifies these are selling stockholder shares and Vor Bio will receive no proceeds from such resales.
Market Pulse Summary
This announcement details standard employee equity inducement grants, including 53,400 stock options and 11,350 RSUs for six new hires at a $13.85 exercise price and four-year vesting schedules. In context, it follows March 2026 financing and Phase 3 trial progress, as well as an S-3 registering 5,338,078 shares from that private placement for resale. Investors may monitor future equity-related filings, trial milestones, and additional hiring trends to gauge longer-term implications.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
AI-generated analysis. Not financial advice.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 53,400 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 11,350 shares of Vor Bio’s common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term, and an exercise price of
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts: Carl Mauch cmauch@vorbio.com